, Volume 169, Issue 5, pp 343–349 | Cite as

Iontophoretic Terbinafine HCL 1.0% Delivery Across Porcine and Human Nails

  • Boaz Amichai
  • Rachel Mosckovitz
  • Henri Trau
  • Orit Sholto
  • Shirly Ben-Yaakov
  • Michael Royz
  • David Barak
  • Boaz Nitzan
  • Avner Shemer



Onychomycosis is a common disease. Topical treatment is usually not effective due to limitation of trans-nail delivery of antifungal drugs. Successful treatment of deep-seated nail infections remains elusive as the delivery of efficacious levels of antifungal drug to the site of action is very difficult.


To evaluate the influence of several parameters including; the effect of low electrical current, incubation time and the presence of electrolyte (NaCl or KCl) on the penetration of terbinafine through the nail plate into the nail bed, using various formulations and concentrations of terbinafine HCl.


Iontophoresis was applied across porcine and human nail in vitro to assess its efficiency in enhancing delivery of terbinafine HCl.


In this study, we have demonstrated that an optimal electrolyte concentration (1% NaCl or KCl) is required for an effective delivery. There is a significant increase in drug delivery into the nail and into the receiving compartment in the presence of 3% DMSO.


This study demonstrates the efficacy of iontophoresis in enhancing the trans-nail delivery of terbinafine. Clinical studies are needed to evaluate the feasibility, efficacy and safety of iontophoresis of terbinafine in onychomycosis in human.


Iontophoresis Nail Terbinafine Onychomycosis 


  1. 1.
    Scher RK. Onychomycosis: therapeutic update. J Am Acad Dermatol. 1999;40(Suppl):S21–6.PubMedGoogle Scholar
  2. 2.
    Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol. 1997;133:1172–3.CrossRefPubMedGoogle Scholar
  3. 3.
    Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;43:641–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Baran R, Hay RJ, Garduno JI. Review of antifungal therapy, part I: treatment rationale, including specific patient populations. J Dermatolog Treat. 2008;19:72–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Baran R, Hay RJ, Garduno JI. Review of antifungal therapy, part II: treatment rationale, including specific patient populations. J Dermatolog Treat. 2008;19:168–75.CrossRefPubMedGoogle Scholar
  6. 6.
    Mehregan DR, Gee SL. The cost effectiveness of testing for onychomycosis versus empiric treatment of onychodystrophies with oral antifungal agents. Cutis. 1999;64:407–10.PubMedGoogle Scholar
  7. 7.
    Gupta AK, Tu LQ. Therapies for onychomycosis: a review. Dermatol Clin. 2006;24:375–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution—an open study of its efficacy in onychomycosis. Clin Exp Dermatol. 1987;12:175–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Shemer A, Trau H, Davidovici B, et al. Onychomycosis- rationalization of topical treatment. IMAJ. 2008;10:415–6.PubMedGoogle Scholar
  10. 10.
    Petranyi G, Meingassner JG, Meith H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother. 1987;31:1365–8.PubMedGoogle Scholar
  11. 11.
    Kim JH, Lee CH, Choi HK. A method to measure the amount of drug penetrated across the nail plate. Pharm Res. 2001;18:1468–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Murthy SN, Wiskirchen DE, Bowers CP. Iontophoretic drug delivery across human nail. J Pharm Sci. 2007;96:305–11.CrossRefGoogle Scholar
  13. 13.
    Murthy SN, Waddell DC, Shivakumar HN, Balaji A, Bowers CP. Iontophoretic permselective property of human nail. J Dermatol Sci. 2007;46:150–2.CrossRefPubMedGoogle Scholar
  14. 14.
    Nair AB, Vaka SR, Sammeta SM, Kim HD, Friden PM, Chakraborty B, et al. Trans-ungual iontophoretic delivery of terbinafine. J Pharm Sci. 2009;98:1788–96.CrossRefPubMedGoogle Scholar
  15. 15.
    Hao J, Li SK. Transungual iontophoretic transport of polar neutral and positively charged model permeants: effects of electrophoresis and electroosmosis. J Pharm Sci. 2008;97:893–905.CrossRefPubMedGoogle Scholar
  16. 16.
    Hao J, Smith KA, Li SK. Chemical method to enhance transungual transport and iontophoresis efficiency. Int J Pharm. 2008;357:61–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Hao J, Li SK. Mechanistic study of electroosmotic transport across hydrated nail plates: effects of pH and ionic strength. J Pharm Sci. 2008;97:1–12.CrossRefGoogle Scholar
  18. 18.
    Kumar MG, Lin S. Transdermal iontophoresis: impact on skin integrity as evaluated by various methods. Crit Rev Ther Drug Carrier Syst. 2008;25:381–401.PubMedGoogle Scholar
  19. 19.
    Dixit N, Baboota S, Ahuja A, Ali J. Iontophoresis—an approach for controlled drug delivery: a review. Curr Drug Deliv. 2007;4:1–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Nolan LM, Corish J, Corrigan OI, Fitzpatrick D. Iontophoretic and chemical enhancement of drug delivery. Part I: across artificial membranes. Int J Pharm. 2003;257:41–55.CrossRefPubMedGoogle Scholar
  21. 21.
    Nolan LM, Corish J, Corrigan OI, Fitzpatrick D. Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin. Int J Pharm. 2007;341:114–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Amichai B, Nitzan B, Mosckovitz R, Shemer A. Iontophoretic terbinafine delivery in onychomycosis—a preliminary study. Br J Dermatol. 2009 Epub ahead of print.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Boaz Amichai
    • 1
  • Rachel Mosckovitz
    • 2
  • Henri Trau
    • 3
  • Orit Sholto
    • 2
  • Shirly Ben-Yaakov
    • 2
  • Michael Royz
    • 2
  • David Barak
    • 2
  • Boaz Nitzan
    • 2
  • Avner Shemer
    • 3
  1. 1.Huzot ClinicClalit Health ServicesAshkelonIsrael
  2. 2.Research DepartmentPower Paper LtdPetah-TikvaIsrael
  3. 3.Dermatology DepartmentSheba Medical CenterTel-HashomerIsrael

Personalised recommendations